

17 July 2012

ASX Announcement  
**Imugene Limited shareholders approve Linguet acquisition**

Consegna Group Limited (“Consegna” or “Company”) is pleased to announce that the shareholders of Imugene Limited (ASX:IMU) today approved a resolution to issue 100,000,000 Imugene shares to Consegna as consideration for the acquisition of Lingual Consegna Pty Ltd by Imugene.

Lingual Consegna, a wholly owned subsidiary of Consegna, owns the rights to a family of patents / patent applications that protect the core delivery drug platform (Linguet) that has applications in the human and animal pharmaceutical and nutraceutical industries.

For further information in relation to the proposed transaction please see the Company’s ASX announcement, “Successful Agreement Reached with Imugene for Sale of Linguet”, released to ASX on 1 May 2012. The Company will make an announcement in regards to the completion of the proposed transaction in due course.

ENDS

**For further information**, please contact Consegna Group Limited on (03) 9417 5001.

**About Consegna Group Limited**

Consegna Group Limited’s purpose is to identify, acquire and commercialise late stage therapeutic delivery technologies. The Company targets high value markets and indications using an acquisition strategy driven by strategic value creation, patent protection and realisation criteria. The Company employs a low fixed overhead model with a panel of successful best in field regulatory, intellectual property and scientific advisors.



**CONSEGNA**  
DELIVERING INNOVATION

‘THE GRAIN STORE’  
7/21 NORTHUMBERLAND ST  
COLLINGWOOD  
MELBOURNE, VIC 3002

TEL. 03 9417 5001  
FAX. 03 8080 0796  
INFO@CONSEGNA.COM

ACN. 107 903 159